Suggestions
Jonathan Wang
Entrepreneur, scientist, investor
Jonathan Wang is a prominent figure in the biopharmaceutical industry with extensive experience in healthcare and life sciences. He is the Founder, Chairman, and CEO of Inmagene Biopharmaceuticals, a global clinical-stage biotechnology company focused on developing novel therapies for immunology-related diseases.12
Education and Early Career
Dr. Wang holds impressive academic credentials:
- Ph.D. in Neurobiology from Columbia University, where he was awarded the Howard Hughes Medical Institute (HHMI) Research Fellowship under the supervision of Nobel Laureate Eric Kandel1
- MBA from Stanford University Graduate School of Business12
Professional Experience
Dr. Wang's career spans over 30 years, encompassing various roles:
- Founder, Chairman, and CEO of Inmagene Biopharmaceuticals (2019-present)2
- Partner at OrbiMed, a leading healthcare-dedicated investment firm, where he co-founded OrbiMed Asia and led the establishment of $1.1B PE/VE funds1
- Board Member and Former Chairman at Apollomics2
- Managing Director at WI Harper Group (2001)2
Achievements at Inmagene Biopharmaceuticals
Under Dr. Wang's leadership, Inmagene has:
- Raised approximately $140 million in financing1
- Developed a strong pipeline with over 10 drug candidates1
- Established wholly owned subsidiaries in San Diego, Shanghai, Hangzhou, and Wuhan1
- Advanced its lead drug candidate, IMG-020, to global phase 2 or 3 trials for 5 autoimmune indications1
Recognition and Contributions
Dr. Wang has been recognized for his contributions to the healthcare industry:
- Named one of the top 10 healthcare investors in China1
- Serves as a HKEX Biotech Advisory Panel member1
- Co-founder and former Chairman of BayHelix, a premier organization of Chinese healthcare business leaders1
Additionally, Dr. Wang has authored two philosophy of science books, further demonstrating his expertise and thought leadership in the field.1
Highlights
When many people dislike BTKi’s, my team persistently pushes our third generation BTKi forward because we think different. We believe our BTKi, uniquely positioned to be dosed once daily, with a wide safety margin, has the potential to be best-in-class.
Inmagene’s anti-OX40 mAb with an extended half-life has dosed the first patient in alopecia areata (AA), a devastating disease which affects approximately 147 million people globally. IMG-007 could potentially provide a safe and effective biologic therapy with once every 12 weeks dosing regimen for AA patients.
